631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II

Emergence of new somatic mutations in CML patients optimally responding to tyrosine kinase inhibitor therapy Proposal of long term genomic monitoring

Functional annotation of MPN clones reveals mutation specific fitness and fate bias

Distinct and non overlapping epigenetic signatures differentiate MPN subtypes and reveal hydroxyurea induced remodeling

Single cell transcriptomic studies reveal altered heterogeneity in CD41 enriched megakaryocytes after targeted therapy in myeloproliferative neoplasm

Investigating the clonal and biological underpinnings of systemic mastocytosis with an associated hematological neoplasm

Spatial transcriptomic dissection of the myeloproliferative neoplasm niche uncovers mutant clone interactions and microenvironmental rewiring

Mutational architecture and clonal heterogeneity in myelofibrosis Prognostic role of variant type and acquisition sequence

Integrative proteomics and machine learning identify subtype and symptom associated signatures in systemic mastocytosis

Allele dependent activity of promoters of genes SLC22A4 and SLC22A5 encoding imatinib transporters in chronic myeloid leukemia

Different kinetic behavior of molecular reduction by BCR ABL1 transcript types in frontline treatment of chronic myeloid leukemia patients A GIMEMA labnet CML network database survey

FBXO3 mediated DUSP9 ubiquitination reprograms MAPK signaling to eradicate tyrosine kinase inhibitor resistant CML stem cells

Unravelling molecular determinants of ruxolitinib treatment response in myelofibrosis using single cell multiomics

Longitudinal genomic shifts associated with disease transformation in patients with polycythemia vera PV enrolled in REVEAL